Boehringer’s lung drug Spiriva, approved for chronic obstructive pulmonary disease (COPD) and asthma, generated net sales of 2.4 billion euros, down 11.4% compared with last year, which the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback